Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines
BACKGROUNDThe United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pai...
Gespeichert in:
| Veröffentlicht in: | Annals of plastic surgery 2021-01, Vol.86 (1), p.11-18 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 18 |
|---|---|
| container_issue | 1 |
| container_start_page | 11 |
| container_title | Annals of plastic surgery |
| container_volume | 86 |
| creator | Crystal, Dustin T. Cuccolo, Nicholas G. Plewinski, Michael J. Ibrahim, Ahmed M.S. Sinkin, Jeremy C. Lin, Samuel J. Agag, Richard L. Lee, Bernard T. |
| description | BACKGROUNDThe United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pain associated with aesthetic plastic surgery procedures, earnest evaluation into opioid-prescribing practices for breast augmentation was conducted.
METHODSMembers of the American Society for Aesthetic Plastic Surgery were electronically surveyed on their opioid-prescribing patterns. The survey was distributed to 1709 plastic surgeons. Descriptive statistics were collated into percentages, deviations, and morphine milligram equivalents (MMEs), when appropriate.
RESULTSTwo hundred twenty-nine American Society for Aesthetic Plastic Surgery members (13.4%) provided responses. A total of 91.2% of respondents prescribe opioids to patients undergoing breast augmentation. The most commonly prescribed agents included oxycodone/acetaminophen (Percocet, 47.0%) and hydrocodone/acetaminophen (Vicodin, 38.3%). On average, 165.3 ± 81.7 MMEs were dispensed (range, 25.0–600.0 MMEs; number tablets, 5–60). Prescribers felt that a lack of phone-in prescribing (52.4%) and the ease of preemptively prescribing opioids (52.4%) propagate opioid overprescribing. A total of 61.3% of respondents reported that they are or may be in favor of developing plastic surgery societal guidelines related to opioid prescribing. These respondents indicated support for guidelines on opioid-sparing pain management strategies (74.2%) and guidelines identifying the type (54.7%), duration of use (69.5%), and number of opioid tablets (61.7%) necessary for procedures.
CONCLUSIONSConsiderable variability exists among prescribing patterns after breast augmentation. Societal guidelines aimed at providers and patients may serve a future role in opioid prescribing. |
| doi_str_mv | 10.1097/SAP.0000000000002430 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2416276152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2416276152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4710-a698e617b93e96e8fd71c506710a51f5a7043b76cb403aa55ad8dd4746c42213</originalsourceid><addsrcrecordid>eNqFkE1L9DAUhYMoOn78A5Es3VTznY678VsQHNB9SdNbzWunGXNbxH9v6-iLuNBsQk6ecy73ELLP2RFnU3t8P5sfsW9HKMnWyIRraTJpWb5OJoyrPLNMyS2yjfiPMS5yZTbJlhTa5FarCYkzREBcQNvRWNO7ZYihyuYJ0KdQhvaRzpPzXfCANLT0NIHDjs76x9HhuhDbE3rZd30Ceh4S-FFBWsdEv2dc9aGCJrSAu2Sjdg3C3ue9Qx4uLx7OrrPbu6ubs9lt5pXlLHNmmoPhtpxKmBrI68pyr5kZ_pzmtXbjVqU1vlRMOqe1q_KqUlYZr4TgcoccrmKXKb70gF2xCOihaVwLscdCKG6ENVyLAVUr1KeImKAuliksXHorOCvGpouh6eJn04Pt4HNCXy6g-m_6qnYA8hXwGpsOEj43_Suk4glc0z39la1-sX5wRtpMMMEZHx7ZqGj5Dksvmmk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2416276152</pqid></control><display><type>article</type><title>Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Crystal, Dustin T. ; Cuccolo, Nicholas G. ; Plewinski, Michael J. ; Ibrahim, Ahmed M.S. ; Sinkin, Jeremy C. ; Lin, Samuel J. ; Agag, Richard L. ; Lee, Bernard T.</creator><creatorcontrib>Crystal, Dustin T. ; Cuccolo, Nicholas G. ; Plewinski, Michael J. ; Ibrahim, Ahmed M.S. ; Sinkin, Jeremy C. ; Lin, Samuel J. ; Agag, Richard L. ; Lee, Bernard T.</creatorcontrib><description>BACKGROUNDThe United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pain associated with aesthetic plastic surgery procedures, earnest evaluation into opioid-prescribing practices for breast augmentation was conducted.
METHODSMembers of the American Society for Aesthetic Plastic Surgery were electronically surveyed on their opioid-prescribing patterns. The survey was distributed to 1709 plastic surgeons. Descriptive statistics were collated into percentages, deviations, and morphine milligram equivalents (MMEs), when appropriate.
RESULTSTwo hundred twenty-nine American Society for Aesthetic Plastic Surgery members (13.4%) provided responses. A total of 91.2% of respondents prescribe opioids to patients undergoing breast augmentation. The most commonly prescribed agents included oxycodone/acetaminophen (Percocet, 47.0%) and hydrocodone/acetaminophen (Vicodin, 38.3%). On average, 165.3 ± 81.7 MMEs were dispensed (range, 25.0–600.0 MMEs; number tablets, 5–60). Prescribers felt that a lack of phone-in prescribing (52.4%) and the ease of preemptively prescribing opioids (52.4%) propagate opioid overprescribing. A total of 61.3% of respondents reported that they are or may be in favor of developing plastic surgery societal guidelines related to opioid prescribing. These respondents indicated support for guidelines on opioid-sparing pain management strategies (74.2%) and guidelines identifying the type (54.7%), duration of use (69.5%), and number of opioid tablets (61.7%) necessary for procedures.
CONCLUSIONSConsiderable variability exists among prescribing patterns after breast augmentation. Societal guidelines aimed at providers and patients may serve a future role in opioid prescribing.</description><identifier>ISSN: 0148-7043</identifier><identifier>EISSN: 1536-3708</identifier><identifier>DOI: 10.1097/SAP.0000000000002430</identifier><identifier>PMID: 32568754</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Analgesics, Opioid - therapeutic use ; Humans ; Mammaplasty ; Pain Management ; Pain, Postoperative - drug therapy ; Practice Patterns, Physicians ; United States</subject><ispartof>Annals of plastic surgery, 2021-01, Vol.86 (1), p.11-18</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4710-a698e617b93e96e8fd71c506710a51f5a7043b76cb403aa55ad8dd4746c42213</citedby><cites>FETCH-LOGICAL-c4710-a698e617b93e96e8fd71c506710a51f5a7043b76cb403aa55ad8dd4746c42213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32568754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crystal, Dustin T.</creatorcontrib><creatorcontrib>Cuccolo, Nicholas G.</creatorcontrib><creatorcontrib>Plewinski, Michael J.</creatorcontrib><creatorcontrib>Ibrahim, Ahmed M.S.</creatorcontrib><creatorcontrib>Sinkin, Jeremy C.</creatorcontrib><creatorcontrib>Lin, Samuel J.</creatorcontrib><creatorcontrib>Agag, Richard L.</creatorcontrib><creatorcontrib>Lee, Bernard T.</creatorcontrib><title>Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines</title><title>Annals of plastic surgery</title><addtitle>Ann Plast Surg</addtitle><description>BACKGROUNDThe United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pain associated with aesthetic plastic surgery procedures, earnest evaluation into opioid-prescribing practices for breast augmentation was conducted.
METHODSMembers of the American Society for Aesthetic Plastic Surgery were electronically surveyed on their opioid-prescribing patterns. The survey was distributed to 1709 plastic surgeons. Descriptive statistics were collated into percentages, deviations, and morphine milligram equivalents (MMEs), when appropriate.
RESULTSTwo hundred twenty-nine American Society for Aesthetic Plastic Surgery members (13.4%) provided responses. A total of 91.2% of respondents prescribe opioids to patients undergoing breast augmentation. The most commonly prescribed agents included oxycodone/acetaminophen (Percocet, 47.0%) and hydrocodone/acetaminophen (Vicodin, 38.3%). On average, 165.3 ± 81.7 MMEs were dispensed (range, 25.0–600.0 MMEs; number tablets, 5–60). Prescribers felt that a lack of phone-in prescribing (52.4%) and the ease of preemptively prescribing opioids (52.4%) propagate opioid overprescribing. A total of 61.3% of respondents reported that they are or may be in favor of developing plastic surgery societal guidelines related to opioid prescribing. These respondents indicated support for guidelines on opioid-sparing pain management strategies (74.2%) and guidelines identifying the type (54.7%), duration of use (69.5%), and number of opioid tablets (61.7%) necessary for procedures.
CONCLUSIONSConsiderable variability exists among prescribing patterns after breast augmentation. Societal guidelines aimed at providers and patients may serve a future role in opioid prescribing.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Humans</subject><subject>Mammaplasty</subject><subject>Pain Management</subject><subject>Pain, Postoperative - drug therapy</subject><subject>Practice Patterns, Physicians</subject><subject>United States</subject><issn>0148-7043</issn><issn>1536-3708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1L9DAUhYMoOn78A5Es3VTznY678VsQHNB9SdNbzWunGXNbxH9v6-iLuNBsQk6ecy73ELLP2RFnU3t8P5sfsW9HKMnWyIRraTJpWb5OJoyrPLNMyS2yjfiPMS5yZTbJlhTa5FarCYkzREBcQNvRWNO7ZYihyuYJ0KdQhvaRzpPzXfCANLT0NIHDjs76x9HhuhDbE3rZd30Ceh4S-FFBWsdEv2dc9aGCJrSAu2Sjdg3C3ue9Qx4uLx7OrrPbu6ubs9lt5pXlLHNmmoPhtpxKmBrI68pyr5kZ_pzmtXbjVqU1vlRMOqe1q_KqUlYZr4TgcoccrmKXKb70gF2xCOihaVwLscdCKG6ENVyLAVUr1KeImKAuliksXHorOCvGpouh6eJn04Pt4HNCXy6g-m_6qnYA8hXwGpsOEj43_Suk4glc0z39la1-sX5wRtpMMMEZHx7ZqGj5Dksvmmk</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Crystal, Dustin T.</creator><creator>Cuccolo, Nicholas G.</creator><creator>Plewinski, Michael J.</creator><creator>Ibrahim, Ahmed M.S.</creator><creator>Sinkin, Jeremy C.</creator><creator>Lin, Samuel J.</creator><creator>Agag, Richard L.</creator><creator>Lee, Bernard T.</creator><general>Lippincott Williams & Wilkins</general><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202101</creationdate><title>Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines</title><author>Crystal, Dustin T. ; Cuccolo, Nicholas G. ; Plewinski, Michael J. ; Ibrahim, Ahmed M.S. ; Sinkin, Jeremy C. ; Lin, Samuel J. ; Agag, Richard L. ; Lee, Bernard T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4710-a698e617b93e96e8fd71c506710a51f5a7043b76cb403aa55ad8dd4746c42213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Humans</topic><topic>Mammaplasty</topic><topic>Pain Management</topic><topic>Pain, Postoperative - drug therapy</topic><topic>Practice Patterns, Physicians</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crystal, Dustin T.</creatorcontrib><creatorcontrib>Cuccolo, Nicholas G.</creatorcontrib><creatorcontrib>Plewinski, Michael J.</creatorcontrib><creatorcontrib>Ibrahim, Ahmed M.S.</creatorcontrib><creatorcontrib>Sinkin, Jeremy C.</creatorcontrib><creatorcontrib>Lin, Samuel J.</creatorcontrib><creatorcontrib>Agag, Richard L.</creatorcontrib><creatorcontrib>Lee, Bernard T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of plastic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crystal, Dustin T.</au><au>Cuccolo, Nicholas G.</au><au>Plewinski, Michael J.</au><au>Ibrahim, Ahmed M.S.</au><au>Sinkin, Jeremy C.</au><au>Lin, Samuel J.</au><au>Agag, Richard L.</au><au>Lee, Bernard T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines</atitle><jtitle>Annals of plastic surgery</jtitle><addtitle>Ann Plast Surg</addtitle><date>2021-01</date><risdate>2021</risdate><volume>86</volume><issue>1</issue><spage>11</spage><epage>18</epage><pages>11-18</pages><issn>0148-7043</issn><eissn>1536-3708</eissn><abstract>BACKGROUNDThe United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pain associated with aesthetic plastic surgery procedures, earnest evaluation into opioid-prescribing practices for breast augmentation was conducted.
METHODSMembers of the American Society for Aesthetic Plastic Surgery were electronically surveyed on their opioid-prescribing patterns. The survey was distributed to 1709 plastic surgeons. Descriptive statistics were collated into percentages, deviations, and morphine milligram equivalents (MMEs), when appropriate.
RESULTSTwo hundred twenty-nine American Society for Aesthetic Plastic Surgery members (13.4%) provided responses. A total of 91.2% of respondents prescribe opioids to patients undergoing breast augmentation. The most commonly prescribed agents included oxycodone/acetaminophen (Percocet, 47.0%) and hydrocodone/acetaminophen (Vicodin, 38.3%). On average, 165.3 ± 81.7 MMEs were dispensed (range, 25.0–600.0 MMEs; number tablets, 5–60). Prescribers felt that a lack of phone-in prescribing (52.4%) and the ease of preemptively prescribing opioids (52.4%) propagate opioid overprescribing. A total of 61.3% of respondents reported that they are or may be in favor of developing plastic surgery societal guidelines related to opioid prescribing. These respondents indicated support for guidelines on opioid-sparing pain management strategies (74.2%) and guidelines identifying the type (54.7%), duration of use (69.5%), and number of opioid tablets (61.7%) necessary for procedures.
CONCLUSIONSConsiderable variability exists among prescribing patterns after breast augmentation. Societal guidelines aimed at providers and patients may serve a future role in opioid prescribing.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>32568754</pmid><doi>10.1097/SAP.0000000000002430</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0148-7043 |
| ispartof | Annals of plastic surgery, 2021-01, Vol.86 (1), p.11-18 |
| issn | 0148-7043 1536-3708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2416276152 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Analgesics, Opioid - therapeutic use Humans Mammaplasty Pain Management Pain, Postoperative - drug therapy Practice Patterns, Physicians United States |
| title | Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T02%3A41%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Opioid-Prescribing%20Practices%20in%20Breast%20Augmentation:%20Future%20Directions%20for%20Prescribing%20Guidelines&rft.jtitle=Annals%20of%20plastic%20surgery&rft.au=Crystal,%20Dustin%20T.&rft.date=2021-01&rft.volume=86&rft.issue=1&rft.spage=11&rft.epage=18&rft.pages=11-18&rft.issn=0148-7043&rft.eissn=1536-3708&rft_id=info:doi/10.1097/SAP.0000000000002430&rft_dat=%3Cproquest_cross%3E2416276152%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2416276152&rft_id=info:pmid/32568754&rfr_iscdi=true |